#1 Clinical Trials Search in Europe

Study on the Effects of D-Cycloserine and Brain Stimulation for Patients with Major Depressive Disorder

2 1 1

What is this study about?

This clinical trial is focused on studying the effects of a treatment for Major Depressive Disorder (MDD), a condition characterized by persistent feelings of sadness and loss of interest. The study will explore the use of a medication called D-cycloserine (DCS) in combination with a technique known as transcranial magnetic stimulation (TMS). TMS is a non-invasive procedure that uses magnetic fields to stimulate nerve cells in the brain, which may help improve symptoms of depression.

The purpose of the study is to investigate whether adding D-cycloserine to a single day of accelerated TMS can enhance its antidepressant effects. Participants will receive either the medication or a placebo alongside TMS. The study will monitor changes in depression symptoms over a period of six weeks, with follow-up assessments at six months to evaluate the long-term effects of the treatment.

Throughout the study, participants will be asked to complete various questionnaires and tests to assess their mood, anxiety levels, and cognitive performance. These assessments will help researchers understand the impact of the treatment on different aspects of mental health. The study aims to provide valuable insights into improving treatment options for individuals with Major Depressive Disorder.

1 joining the study

Upon joining the study, you will be assessed to confirm your eligibility. This includes verifying that you have a primary diagnosis of major depressive disorder (MDD) with a current moderate to severe depressive episode, are aged between 18-65 years, and have tried at least two types of antidepressant medication without sufficient results.

2 treatment day

On the treatment day, you will receive a single session of accelerated transcranial magnetic stimulation (TMS). This is a non-invasive procedure that uses magnetic fields to stimulate nerve cells in the brain.

You will also be administered D-cycloserine (DCS) in the form of a hard capsule. The dosage and specific instructions for taking this medication will be provided by the study team.

3 post-treatment monitoring

After the treatment, your progress will be monitored weekly for six weeks. This involves measuring the percentage reduction from your baseline Montgomery-Åsberg Depression Rating Scale (MADRS) score.

You will also complete a side effect questionnaire immediately after the treatment to report any adverse effects you may experience.

4 follow-up assessments

At six weeks post-treatment, your clinical remission and response will be evaluated. Clinical remission is defined as a MADRS score of 8 or less, and clinical response is a reduction from baseline MADRS score of more than 50%.

You will also complete an EQ5D questionnaire at this time to assess your overall health status.

5 extended follow-up

Your progress will continue to be monitored monthly for the remainder of six months. This includes measuring the percentage reduction from baseline scores on the Generalized Anxiety Disorder 7-item (GAD-7) scale and the Patient Health Questionnaire-9 (PHQ-9).

At six months, a final assessment will be conducted to evaluate the long-term effects of the treatment.

Who Can Join the Study?

  • A primary diagnosis of Major Depressive Disorder (MDD), with a current moderate to severe depressive episode. This means a score of more than 20 on a specific depression rating scale called the MADRS.
  • Age between 18-65 years old.
  • A diagnosis of moderate to severe treatment-resistant depression (TRD). This means you have tried at least 2 types of antidepressant medication without getting enough relief.

Who Cannot Join the Study?

  • Patients with any other psychiatric disorder besides Major Depressive Disorder (MDD) cannot participate. This means if you have another mental health condition, you may not be eligible.
  • Patients who have a history of seizures or epilepsy cannot participate. Seizures are sudden, uncontrolled electrical disturbances in the brain.
  • Patients with metal implants in the head, except for dental fillings, cannot participate. Metal implants can interfere with the study equipment.
  • Patients who are currently using medications that affect the brain and cannot be safely stopped for the study duration cannot participate. This includes certain antidepressants or antipsychotics.
  • Patients with a history of substance abuse or dependence within the past year cannot participate. Substance abuse refers to the harmful use of substances like alcohol or drugs.
  • Patients who are pregnant or breastfeeding cannot participate. This is to ensure the safety of both the mother and the child.
  • Patients with unstable medical conditions cannot participate. An unstable condition is one that is not well-controlled or is changing rapidly.
  • Patients who have participated in another clinical trial within the last 30 days cannot participate. This is to avoid interference between studies.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

Site Name City Country Status
University Hospital Maastricht Maastricht The Netherlands

Other Sites

No sites found in this category

Want to learn more about this study or check if you can participate? Contact us.

Trial status

Country Status Recruitment Start
The Netherlands The Netherlands
Not yet recruiting
01.05.2025

Trial locations

D-cycloserine is a medication that is being studied for its potential to enhance the effects of transcranial magnetic stimulation (TMS) in treating depression. It is thought to work by affecting certain brain chemicals that are involved in mood regulation. In this trial, D-cycloserine is used to see if it can make TMS more effective in reducing symptoms of depression.

Transcranial Magnetic Stimulation (TMS) is a non-invasive therapy that uses magnetic fields to stimulate nerve cells in the brain. It is used to treat depression, especially in cases where other treatments have not been effective. In this trial, TMS is being used in an accelerated form, meaning the sessions are more frequent, to see if it can quickly reduce depressive symptoms when combined with D-cycloserine.

Investigated diseases:

Major Depressive Disorder (MDD) – Major Depressive Disorder is a mental health condition characterized by persistent feelings of sadness, hopelessness, and a lack of interest or pleasure in activities. It affects how a person feels, thinks, and handles daily activities, such as sleeping, eating, or working. The disorder can lead to a variety of emotional and physical problems, making it difficult for individuals to function at work and in their personal lives. Symptoms may include changes in appetite or weight, sleep disturbances, fatigue, and difficulty concentrating. The progression of MDD can vary, with some individuals experiencing episodes that last for weeks or months, while others may have recurrent episodes throughout their lives. The severity and duration of symptoms can differ from person to person.

Trial ID:
2025-521166-95-00
Trial Phase:
Therapeutic exploratory (Phase II)

Other Trials to Consider

  • Assessment of NBI-1065845 as an Additional Treatment for Adults with Major Depressive Disorder

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Bulgaria Lithuania Romania Slovakia

  • Evaluating NBI-1065845 as an Additional Treatment for Adults with Major Depressive Disorder Who Are Not Responding Adequately to Current Therapy

    Recruiting

    3 1
    Investigated diseases:
    Investigated drugs:
    Belgium Finland Hungary Latvia